Genzyme GMP failures now irk patients as well as regulators, lawyers and shareholders; Baxter expands for cytotoxics in Germany;

> Some Genzyme patients have told the New York Times that they feel "betrayed" by the drug company they once viewed as savior, wondering why Genzyme had insufficient reserves of drugs vital to them, and how it could have responded so poorly in fixing its manufacturing problems. Article

> Baxter is expanding its cytotoxic contract manufacturing facility in Halle, Germany, for the third time. Article

> Russian homeopathic drug manufacturer of Materia Medica has signed with contract manufacturer Angel Biotechnology for process development and GMP manufacture of specific antibodies. Article

> DHL reports "a record number of movements" of finished pharmaceuticals, vaccines, medical equipment and devices, and clinical trial supplies in Asia, yielding 7 percent growth in its Life Sciences & Healthcare business. Item

> Corning is displaying its newest glass reactor product, a low-flow glass reactor that the company says aids in the transition to higher-volume, continuous-flow chemical processing, at Interphex. Release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.